SLNO — Soleno Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.76bn
- $2.56bn
- $190.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11 | ||
| PEG Ratio (f) | 0.17 | ||
| EPS Growth (f) | 180.77% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.57 | ||
| Price to Tang. Book | 5.62 | ||
| Price to Free Cashflow | 26.21 | ||
| Price to Sales | 9.69 | ||
| EV to EBITDA | 28.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.71% | ||
| Return on Equity | 26.27% | ||
| Operating Margin | 30.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 190.41 | 467.53 | 703.04 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +910.08 | +59.19 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
Directors
- Ernest Mario NEC (82)
- Anish Bhatnagar PRE (53)
- James Mackaness CFO (57)
- Patricia Hirano VPR (55)
- Kristen Yen VPR (52)
- William Harris IND (63)
- Gwen Melincoff IND (69)
- Andrew Sinclair IND (49)
- Birgitte Volck IND (58)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- August 25th, 1999
- Public Since
- October 23rd, 2014
- No. of Shareholders
- 31
- No. of Employees
- 182
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 52,120,147
- Address
- 100 Marine Parkway, Suite 400, REDWOOD CITY, 94065
- Web
- https://soleno.life/
- Phone
- +1 3026587581
- Auditors
- Marcum LLP
Upcoming Events for SLNO
Similar to SLNO
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Soleno Therapeutics share price?
As of Today at 23:21 UTC, shares in Soleno Therapeutics are trading at $53.01. This share price information is delayed by 15 minutes.
How has the Soleno Therapeutics share price performed this year?
Shares in Soleno Therapeutics last closed at $53.01 and the price had moved by -29.39% over the past 365 days. In terms of relative price strength the Soleno Therapeutics share price has underperformed the S&P500 Index by -43.21% over the past year.
What are the analyst and broker recommendations for Soleno Therapeutics?
The overall consensus recommendation for Soleno Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Soleno Therapeutics dividend yield?
Soleno Therapeutics does not currently pay a dividend.
Does Soleno Therapeutics pay a dividend?
Soleno Therapeutics does not currently pay a dividend.
When does Soleno Therapeutics next pay dividends?
Soleno Therapeutics does not currently pay a dividend.
How do I buy Soleno Therapeutics shares?
To buy shares in Soleno Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Soleno Therapeutics?
As of the previous close price of $53.01, shares in Soleno Therapeutics had a market capitalisation of $2.76bn.
Where are Soleno Therapeutics shares listed?
Here are the trading details for Soleno Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SLNO
What kind of share is Soleno Therapeutics?
Based on an overall assessment of its quality, value and momentum Soleno Therapeutics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Soleno Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in Soleno Therapeutics is $56.40. That is 6.4% above the last closing price of $53.01.
Analysts covering Soleno Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $3.95 for the next financial year.
Find out moreWhat is the trend in the Soleno Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Soleno Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -3.39%.
As of the last closing price of $53.01, shares in Soleno Therapeutics were trading +0.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Soleno Therapeutics PE Ratio?
The Soleno Therapeutics PE ratio based on its reported earnings over the past 12 months is 11. The shares last closed at $53.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Soleno Therapeutics?
Soleno Therapeutics' management team is headed by:
- Ernest Mario - NEC
- Anish Bhatnagar - PRE
- James Mackaness - CFO
- Patricia Hirano - VPR
- Kristen Yen - VPR
- William Harris - IND
- Gwen Melincoff - IND
- Andrew Sinclair - IND
- Birgitte Volck - IND